Powered By Purpose

Q2 2021 Earnings Call
August 3, 2021

AGENDA

INTRODUCTION AND KEY RECENT EVENTS

Dave Ricks, Chairman and Chief Executive Officer

Q2 2021 FINANCIAL RESULTS

Anat Ashkenazi, Chief Financial Officer

R&D UPDATE

Dan Skovronsky, M.D., Ph.D., Chief Scientific and Medical Officer

CLOSING REMARKS

Dave Ricks, Chairman and Chief Executive Officer

QUESTION AND ANSWER SESSION

SAFE HARBOR PROVISION

This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ materially due to various factors. The company's results may be affected by factors including, but not limited to, the risks and uncertainties in pharmaceutical research and development; competitive developments; regulatory actions; the extent and duration of the effects of the COVID-19 pandemic; litigation and investigations; business development transactions; economic conditions; and changes in laws and regulations, including health care reform.

For additional information about the factors that affect the company's business, please see the company's latest Forms 10-K,10-Q, and any 8-Ks filed with the Securities and Exchange Commission. Certain financial information in this presentation is presented on a non-GAAP basis. Investors should refer to the reconciliations included in this presentation and should consider the company's non-GAAP measures in addition to, not as a substitute for or superior to, measures prepared in accordance with GAAP.

The company undertakes no duty to update forward-looking statements except as required by applicable law

STRATEGIC DELIVERABLES

PROGRESS SINCE THE LAST EARNINGS CALL

Grow Revenue

- 19% revenue growth YTD; 11% growth excluding COVID-19 antibody revenue
- 23% revenue growth in Q2; 12% growth excluding COVID-19 antibody revenue, Q2 2020 COVID-19 related de-stocking, and divestiture of Cialis in China
- Q2 revenue growth driven by:
  - 22% volume growth
  - Key growth products, which accounted for 54% of core business revenue

Improve Productivity

- Non-GAAP gross margin
  - 79.3% in Q2 (79.7% excluding FX impact on international inventories sold)
  - 77.3% YTD (78.8% excluding FX impact on international inventories sold)
- Non-GAAP operating margin
  - 29.4% in Q2, +140 basis points compared with prior year
  - 28.5% YTD, -60 basis points compared with prior year

Create Long-Term Value

- Acquired Protomer Technologies
- Distributed nearly $800 million via dividends in Q2
- Completed $500 million in share repurchases in Q2
- Authorized new $5 billion share repurchase program

Speed Life-Changing Medicines

- Positive results from SURPASS-4 trial of tirzepatide in type 2 diabetes; submission expected by the end of 2021
- Positive results from EMPEROR-Preserved trial of Jardiance® in heart failure with preserved ejection fraction and EU approval for Jardiance in heart failure with reduced ejection fraction
- Phase 3 initiations for pirtobrutinib in MCL, tirzepatide in HFpEF, and Verzenio® in prostate cancer and HR+ HER2+ early breast cancer
- U.S. FDA Breakthrough Therapy designation for donanemab; submission expected by the end of 2021

Jardiance is part of the Boehringer Ingelheim (BI) and Lilly Alliance, and BI holds the marketing authorization for Jardiance.

KEY EVENTS SINCE THE LAST EARNINGS CALL

REGULATORY

- The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for **donanemab** for Alzheimer's disease, and Lilly intends to submit a registration package to regulatory authorities by the end of 2021;
- The **tirzepatide** SURPASS program has met global regulatory submission requirements for evaluating cardiovascular risk, and Lilly intends to submit a registration package to regulatory authorities in the U.S. by the end of 2021;
- The European Commission granted marketing authorization for **Jardiance** for adults with symptomatic chronic heart failure with reduced ejection fraction; and
- The FDA will not meet the early Q3 Prescription Drug User Fee Act action date for the supplemental new drug application (sNDA) for **baricitinib** for the treatment of adults with moderate to severe atopic dermatitis.

CLINICAL

- **Tirzepatide** led to superior A1C and body weight reductions from baseline across all three doses in adults with type 2 diabetes who have increased cardiovascular risk compared to titrated insulin glargine in the SURPASS-4 clinical trial;

CLINICAL (CONT)

- **Jardiance** significantly reduced the risk of the composite of cardiovascular death or hospitalization for heart failure in adults, with or without diabetes, who live with heart failure with preserved ejection fraction;
- **Tanezumab** demonstrated statistically significant improvement in daily average pain intensity compared to placebo in patients receiving background opioid therapy in adults with moderate to severe cancer pain due to bone metastases or multiple myeloma. Preliminary safety data showed that during the 24-week treatment period, the adverse event profile was generally consistent with the adverse events expected in patients with cancer pain due to bone metastasis and the known safety profile of tanezumab; and
- Announced plans to conduct a head-to-head study comparing **Emgality**® with Nurtec® ODT.

BUSINESS DEVELOPMENT

- Announced a global research collaboration with **MiNA Therapeutics Limited** to develop novel drug candidates using MiNA's proprietary small activating RNA (saRNA) technology platform;

KEY EVENTS SINCE THE LAST EARNINGS CALL

BUSINESS DEVELOPMENT (CONT)

- Announced the acquisition of **Protomer Technologies**, whose proprietary peptide- and protein-engineering platform is used to identify and synthesize molecules that can sense glucose or other endogenous modulators of protein activity;
- Announced an exclusive collaboration with **Kumquat Biosciences** focused on the discovery, development and commercialization of potential novel small molecules that stimulate tumor-specific immune responses utilizing its immuno-oncology platform;
- Announced a strategic research collaboration with Banner Alzheimer's Institute as part of the planned Phase 3 study evaluating **donanemab** in participants at risk for cognitive and functional decline related to Alzheimer's disease; and
- Announced strategic international agreements with four companies – **DexCom Inc.**, **Glooko Inc.**, **myDiabby Healthcare** and **Roche** – to advance connected solutions and streamline care for people living with diabetes in markets outside of the U.S.

COVID-19 & OTHER

- Announced donations of **COVID-19 therapies** to Direct Relief, enabling the humanitarian organization to provide COVID-19 therapies at no cost to low- and lower-middle-income countries most heavily impacted by the pandemic;
- Halted shipments of **bamlanivimab and etestevimab** in the U.S. given the prevalence of the Gamma and Beta variants at that time;
- The FDA has broadened the Emergency Use Authorization (EUA) for **baricitinib** to allow for treatment with or without remdesivir, whereas the EUA was previously restricted to use only in combination with remdesivir;
- Outlined an updated **Environmental, Social and Governance** (ESG) strategy, and launched a new comprehensive resource to provide increased transparency regarding the company's ESG goals and progress;
- Authorized a new $5 billion **share repurchase program**; $500 million still remains under the program authorized in June 2018; and
- Announced support of Direct Relief's Fund for Health Equity with a $5 million commitment over the next five years, which is a component of the company's **Racial Justice Initiative**.

RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION; CERTAIN LINE ITEMS (UNAUDITED)

Millions; except per share data

	Q2 2021			
	GAAP Reported	Adjustments	Non-GAAP Adjusted	Non-GAAP Adjusted Change
TOTAL REVENUE	$6,740	-	**$6,740**	23%
GROSS MARGIN	71.0%	8.3%	**79.3%**	(0.3)pp
TOTAL OPERATING EXPENSE	3,384	(25)	**3,359**	18%
OPERATING INCOME	1,403	581	**1,984**	29%
OPERATING MARGIN	20.8%	8.6%	**29.4%**	1.4pp
OTHER INCOME (EXPENSE)	191	(186)	**5**	NM
EFFECTIVE TAX RATE	12.8%	1.6%	**14.4%**	3.5pp
NET INCOME	$1,390	313	**$1,703**	29%
EPS	$1.53	$0.34	**$1.87**	29%

Note: Numbers may not add due to rounding; see slide 28 for a complete list of significant adjustments.

RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION; CERTAIN LINE ITEMS (UNAUDITED)

Millions; except per share data

	YTD 2021			
	GAAP Reported	Adjustments	Non-GAAP Adjusted	Non-GAAP Adjusted Change
TOTAL REVENUE	$13,546	-	**$13,546**	19%
GROSS MARGIN	71.7%	5.6%	**77.3%**	(2.7)pp
TOTAL OPERATING EXPENSE	7,155	(536)	**6,619**	15%
OPERATING INCOME	2,559	1,298	**3,857**	17%
OPERATING MARGIN	18.9%	9.6%	**28.5%**	(0.6)pp
OTHER INCOME (EXPENSE)	512	(472)	**40**	NM
EFFECTIVE TAX RATE	10.6%	2.0%	**12.6%**	0.7pp
NET INCOME	$2,746	659	**$3,405**	22%
EPS	$3.01	$0.73	**$3.74**	22%

Note: Numbers may not add due to rounding; see slide 28 for a complete list of significant adjustments.

PRICE/RATE/VOLUME EFFECT ON REVENUE

Millions

	Q2 2021					
	Amount	Price	FX Rate	Volume	Total	CER
U.S.	$3,704	(1)%	-	18%	18%	18%
EUROPE	1,210	(1)%	11%	28%	38%	27%
JAPAN	665	(3)%	(2)%	5%	(0)%	2%
CHINA	523	(19)%	12%	125%	118%	106%
REST OF WORLD	638	(2)%	6%	7%	11%	5%
TOTAL REVENUE	$6,740	(2)%	3%	22%	23%	20%

	YTD 2021					
	Amount	Price	FX Rate	Volume	Total	CER
U.S.	$7,645	(3)%	-	21%	18%	18%
EUROPE	2,531	(1)%	10%	21%	31%	20%
JAPAN	1,237	(3)%	1%	(0)%	(2)%	(3)%
CHINA	885	(12)%	10%	76%	74%	64%
REST OF WORLD	1,247	(2)%	3%	4%	5%	2%
TOTAL REVENUE	$13,546	(3)%	3%	20%	19%	17%

Note: Numbers may not add due to rounding

CER = price change + volume change

KEY PRODUCTS DRIVING WW VOLUME GROWTH

Contribution to 22% Q2 WW Volume Growth



Numbers may not add due to rounding

* includes Cyramza®, Emgality, Jardiance, Olumiant®, Retevmo®, Taltz®, Trulicity®, Tyvyt®, and Verzenio

** LOE: loss of exclusivity; includes Axiron®, Cialis®, Cymbalta®, Effient®, Evista®, Strattera®, and Zyprexa®

Jardiance is part of the Boehringer Ingelheim (BI) and Lilly Alliance

Note: COVID-19 antibody sales were made pursuant to Emergency Use Authorization

UPDATE ON KEY GROWTH PRODUCTS



Note: Jardiance is sold by Boehringer Ingelheim; Lilly records as revenue its share of Jardiance gross margin; Jardiance is part of the Boehringer Ingelheim and Lilly Alliance

RETEVMO
- U.S. approval May 2020 in advanced RET-driven lung and thyroid cancers

TYVYT
- Increasing PD-1 penetration in China
- Launch of HCC and sq NSCLC indications

EMGALITY
- U.S. NBRx SOM 40% at the end of Q2 2021
- U.S. TRx 37% SOM at end of Q2 2021

VERZENIO
- U.S. NBRx SOM nearly 27%
- U.S. TRx grew 41% vs. Q2 2020, outpacing the market

OLUMIANT
- OUS sales grew 45% vs. Q2 2020

TALTZ
- IL-17 dermatology leader in U.S. TRx SOM 19%
- U.S. TRx grew 29% vs. Q2 2020

JARDIANCE
- Market leader in U.S. TRx SOM 60% and NTS SOM nearly 59%
- U.S. SGLT2 class grew 23% vs. Q2 2020

CYRAMZA
- WW sales growth +5% vs. Q2 2020

TRULICITY
- Market leader in U.S. TRx SOM nearly 49% (injectable GLP-1) at end of Q2
- U.S. injectable GLP-1 class grew 22% vs. Q2 2020

CAPITAL ALLOCATION

Billions

YTD 2021 Capital Allocation



* After-tax
** Includes cash outflows associated with equity investments

2021 GUIDANCE

	Prior	Updated	Comments
TOTAL REVENUE	$26.6 – $27.6 billion	$26.8 – $27.4 billion	Reflects $200 million increase in the core business due to strong performance and favorable FX and $400 decrease in the top end of the COVID-19 antibodies range
GROSS MARGIN % (GAAP)	Approx. 77%	Approx. 75%	Reflects impact of excess inventory charges for COVID-19 antibodies due to combination of current/revised forecasted demand from U.S. and OUS governments and near-term expiry dates of COVID-19 antibodies
GROSS MARGIN % (NON-GAAP)	Approx. 79%	Unchanged	
MKTG, SELLING & ADMIN.	$6.2 – $6.4 billion	Unchanged	Trending toward top end of the range
RESEARCH & DEVELOPMENT	$6.9 – $7.1 billion	Unchanged	Trending toward top end of the range
OTHER INCOME/(EXPENSE) (GAAP)	$150 – $250 million	$375 – $475 million	Reflects the impact of net gains on investments in equity securities in the second quarter and Alimta patent settlements in Europe
OTHER INCOME/(EXPENSE) (NON-GAAP)	$(200) – $(100) million	$(100) million – $0	Reflects Alimta patent settlements in Europe
TAX RATE (GAAP)	Approx. 13%	Approx. 12%	Reflects the impact of excess inventory charges related to COVID-19 antibodies
TAX RATE (NON-GAAP)	Approx. 13%	Unchanged	
EARNINGS PER SHARE (GAAP)	$7.03 – $7.23	$6.73 - $6.93	Reflects the impact of excess inventory charges related to COVID-19 antibodies and the impact of net gains on investments in equity securities
EARNINGS PER SHARE (NON-GAAP)	$7.80 – $8.00	Unchanged	
OPERATING INCOME % (GAAP)	Approx. 26%	Approx. 24%	Reflects the impact of excess inventory charges related to COVID-19 antibodies and the impact of lower COVID-19 antibody revenue
OPERATING INCOME % (NON-GAAP)	Approx. 31%	Approx. 30%	Reflects the impact of lower COVID-19 antibody revenue

Assumes GAAP and non-GAAP shares outstanding 909 million

Updated FX assumptions of 1.19 (Euro), 111 (Yen) and 6.47 (Renminbi)

DONANEMAB: AAIC HIGHLIGHTS

CONSISTENCY OF CLINICAL BENEFIT ACROSS STATISTICAL METHODS

Consistency of TRAILBLAZER-ALZ Results Across Statistical Methods



DPM = Disease Progression Model; MMRM = Mixed Model for Repeated Measure; NCS2 = Natural Cubic Spline with 2 degrees of freedom; NCS3 = Natural Cubic Spline with 3 degrees of freedom; QMM = Quadratic Mixed Model; For frequentist analyses *p<0.05; **p<0.01 vs. placebo; for DPM ++ indicates posterior probability of at least 0% slowing >99%; iADRS = Integrated Alzheimer's Disease Rating Scale; CDR-SB = Clinical Dementia Rating-Sum of Boxes

DONANEMAB: AAIC HIGHLIGHTS

Relationship between decreasing amyloid plaque and slowing clinical progression using the Conrado model*



- In TRAILBLAZER-ALZ disease progression on iADRS was reduced by 28% in overall donanemab treated population (p<0.001)
- Highly significant relationship between degree of plaque reduction and slowing of cognitive decline (p<0.001)
- Important support for use of plaque reduction as surrogate biomarker for efficacy
- Model solution shows that patients who achieve 100% clearance will have 40% slowing versus predicted disease course without therapy

*An updated Alzheimer's disease progression model incorporating non-linearity, beta regression, and a third-level random effect in non-linear mixed effects modeling, Conrado DJ et al. J Pharmacokinet Pharmacodyn, 2014; iADRS = Integrated Alzheimer's Disease Rating Scale; CI = Confidence interval; p = p-value

DONANEMAB: AAIC HIGHLIGHTS

CORRELATION BETWEEN PLAQUE CLEARANCE AND SPREAD OF TAU PATHOLOGY

MULTIPLE MEASURES OF AD TAU PATHOLOGY SHOWN TO PREDICT FUTURE RATE OF DECLINE

- Level of tau pathology imaged by PET corresponds to future decline using either quantitative measures[1,2] or visual interpretation[3]
- Plasma phospho-tau217 (P-tau217) is tightly associated with AD pathology and has recently been shown to predict progression to dementia[4]
- Data from TRAILBLAZER-ALZ also showed tau pathology at baseline corresponded to subsequent rate of decline in the placebo treated patients (correlation of frontal lobe tau to decline by iADRS significant at p=0.0012)

IMPACT OF PLAQUE CLEARANCE ON TAU PATHOLOGY IN TRAILBLAZER-ALZ



- Donanemab decreased regional brain tau accumulation in TRAILBLAZER-ALZ
- Greatest effect in patients who achieved complete plaque clearance by 24 weeks

[1]Ossenkoppele et al, JAMA Neurology, 2021; [2]Pontecorvo et al, BRAIN, 2019; [3]Lu et al, JAMA Neurology, 2021; [4]Palmqvist et al, NATURE Medicine, 2021; AD = Alzheimer's Disease; PET = Positron Emission Tomography; iADRS = Integrated Alzheimer's Disease Rating Scale

Impact of plaque clearance on tau pathology: bars show least square mean +/- standard error of cortical tau level measured using regional tau PET standardized uptake value ratio (cere-crus as reference region) *p<0.05; **p<0.01 vs. placebo

DONANEMAB: AAIC HIGHLIGHTS

PLASMA P-TAU217 ANALYSIS

DONANEMAB TREATMENT DELIVERS EARLY REDUCTION OF PLASMA P-TAU217



Line shows least square mean of log adjusted plasma pTau217 by MMRM

** p<0.01; *** p<0.001; **** p<0.0001 vs. placebo

DECREASED PLASMA P-TAU217 ASSOCIATED WITH AMYLOID PLAQUE CLEARANCE AT 76 WEEKS



LS = Least Square; PET = Positron Emission Tomography; MMRM = Mixed Model for Repeated Measure; CL= centiloids; p = p-value; R = correlation coefficient

DONANEMAB: AAIC HIGHLIGHTS

Relationship between decreasing P-tau217 and slowing clinical progression using the Conrado model*



- Highly significant relationship between degree of plasma P-tau217 reduction and slowing of cognitive decline (p<0.001)
- Additional biomarker for efficacy, linking the donanemab mechanism of plaque clearance with positive effects on both clinical outcomes and brain tau pathology
- Model solution shows that patients who achieve 30% decrease will have 40% slowing versus predicted disease course without therapy

In TRAILBLAZER-ALZ disease progression on iADRS was reduced by 28% in overall donanemab treated population (p<0.001)

*An updated Alzheimer's disease progression model incorporating non-linearity, beta regression, and a third-level random effect in non-linear mixed effects modeling, Conrado DJ et al. J Pharmacokinet Pharmacodyn, 2014; iADRS = Integrated Alzheimer's Disease Rating Scale; CI = Confidence interval; p = p-value

REGULATORY UPDATES

DONANEMAB

VERZENIO

OLUMIANT



LILLY SELECT NME AND NILEX PIPELINE

JULY 30, 2021

LEGEND

- NME
- NILEX
- * *Commercial Collaboration*

MOVEMENT SINCE April 23, 2021

- ADDITION or MILESTONE ACHIEVED
- REMOVAL

^ *Emergency Use Authorization has been granted in the US and other countries*

PHASE 1

- KRAS G12C II — Cancer
- LP(a) siRNA — CVD
- SERD — Cancer
- TRPA1 ANTAGONIST — Pain
- GIPR AGONIST LA II — Diabetes
- PYY ANALOG — Diabetes
- RELAXIN-LA — Heart Failure
- RIPK1 INHIBITOR — Immunology
- O-GLCNACASE INH — Alzheimer's
- OXYNTOMODULIN — Diabetes
- P2X7 INHIBITOR — Pain
- N3PG Aβ MAB — Alzheimer's
- NOT DISCLOSED — Diabetes
- NRG4 AGONIST — Heart Failure
- KHK INHIBITOR — Diabetes / NASH
- KHK INHIBITOR II — Diabetes / NASH
- LP(a) INHIBITOR — CVD
- GLP-1R NPA — Diabetes
- IDH1 INHIBITOR — Cancer
- IL-17A SMALL MOL INHIBITOR — Immunology
- CD200R MAB AGONIST — Immunology
- GIP/GLP COAGONIST PEPTIDE — Diabetes
- GIPR AGONIST LA — Diabetes
- ANGPTL3 siRNA — CVD
- AUR A KINASE INHIBITOR — Cancer
- BTLA MAB AGONIST — Immunology

PHASE 2

- GBA1 GENE THERAPY — Gaucher Disease Type 2
- TIRZEPATIDE — NASH
- GGG TRI-AGONIST — Obesity
- IL-2 CONJUGATE — Ulcerative Colitis
- PIRTOBRUTINIB (LOXO-305) — B-Cell Malignancies
- GGG TRI-AGONIST — Diabetes
- BEBTELOVIMAB (LY-CoV1404 MAB) — COVID-19
- SSTR4 AGONIST — Pain
- ZAGOTENEMAB — Alzheimer's
- PACAP38 MAB — Migraine
- PD-1 MAB AGONIST — Rheumatoid Arthritis
- IL-2 CONJUGATE — Systemic Lupus Erythematosus
- MEVIDALEN — Symptomatic LBD
- GBA1 GENE THERAPY — Parkinson's Disease
- GRN GENE THERAPY — Frontotemporal Dementia
- CXCR1/2L MAB — Hidradenitis Suppurativa
- EPIREG/TGFα MAB — Chronic Pain
- AUTOMATED INSULIN DELIVERY SYS — Diabetes
- BASAL INSULIN-FC — Diabetes

PHASE 3

- PIRTOBRUTINIB (LOXO-305) — R/R MCL Monotherapy
- TIRZEPATIDE — Heart Failure pEF
- ABEMACICLIB — HER2+ Early BC
- ABEMACICLIB — Prostate Cancer
- TIRZEPATIDE — CV Outcomes
- TIRZEPATIDE — Obesity
- SELPERCATINIB — 1L Med Thyroid Cancer
- TANEZUMAB* — Cancer Pain
- MIRIKIZUMAB — Crohn's Disease
- SELPERCATINIB — 1L NSCLC
- EMPAGLIFLOZIN* — Chronic Kidney Disease
- EMPAGLIFLOZIN* — Post MI
- BARICITINIB — Systemic Lupus Erythematosus
- EMPAGLIFLOZIN* — Heart Failure pEF
- SOLANEZUMAB — Preclinical AD
- TIRZEPATIDE — Diabetes
- MIRIKIZUMAB — Ulcerative Colitis
- PIRTOBRUTINIB (LOXO-305) — R/R CLL monotherapy
- DONANEMAB — Early Alzheimer's
- LEBRIKIZUMAB — Atopic Dermatitis

REG REVIEW

- BARICITINIB — Alopecia Areata
- CONNECTED CARE PREFILLED INSULIN PEN — Diabetes
- ABEMACICLIB — Adjuvant Breast Cancer
- SINTILIMAB (US)* — NonSquam NSCLC 1L
- TANEZUMAB* — Osteoarthritis Pain
- BAMLANIVIMAB & ETESEVIMAB^ — COVID-19

APPROVED

- EMPAGLIFLOZIN* — Heart Failure rEF

PHASE 1 (removal)

- GIP/GLP COAGONIST PEPTIDE II — Diabetes

New since last update

POTENTIAL KEY EVENTS 2021

Phase 3 Initiations

- **Abemaciclib** for HR+, HER2+ early breast cancer
- **Abemaciclib** for prostate cancer
- **Pirtobrutinib (LOXO-305)** for MCL monotherapy
- **Pirtobrutinib (LOXO-305)** for CLL monotherapy
- **Pirtobrutinib (LOXO-305)** for CLL combination therapy
- **Pirtobrutinib (LOXO-305)** for CLL first-line
- **Tirzepatide** for obesity (3 additional studies)
- **Tirzepatide** for HFpEF
- **Donanemab** for asymptomatic Alzheimer's disease
- **Oral SERD** for metastatic breast cancer

Phase 3 & Other Key Data Disclosures

- **Baricitinib** for alopecia areata
- **Baricitinib** for systemic lupus erythematosus
- **Donanemab** for early Alzheimer's disease
- **Empagliflozin** for HFpEF[1]
- **Lebrikizumab** for atopic dermatitis
- **Mirikizumab** for ulcerative colitis (induction data)
- **Mirikizumab** for ulcerative colitis (maintenance data)
- **Tirzepatide** for type 2 diabetes (SURPASS-2)
- **Tirzepatide** for type 2 diabetes (SURPASS-3)
- **Tirzepatide** for type 2 diabetes (SURPASS-4)
- **Tirzepatide** for type 2 diabetes (SURPASS-5)
- **Zagotenemab** for early Alzheimer's disease

Medical Meeting Presentations

- **Donanemab** for early Alzheimer's disease
- **Oral SERD** for metastatic breast cancer
- **Tirzepatide** for type 2 diabetes (SURPASS 1 / 2 / 3 / 4 / 5)

Regulatory Submissions

- **Abemaciclib** for high-risk HR+, HER2- early breast cancer (J)
- **Baricitinib** for alopecia areata (US/EU/J)
- **Bamlanivimab + Etesevimab** for COVID-19 (EU /US)
- **Sintilimab** for NSCLC (US)
- **Tirzepatide** for type 2 diabetes (US/EU/J)
- **Donanemab** for early Alzheimer's disease
- **Empagliflozin** for HFpEF[1]

Regulatory Actions

- **Abemaciclib** for high-risk HR+, HER2- early breast cancer (US/EU/J)
- **Baricitinib** for atopic dermatitis (US/J)[3]
- **Baricitinib** for COVID-19 (J)
- **Empagliflozin** for HFrEF (US/EU /J)[1]
- **Selpercatinib** for NSCLC and thyroid cancers (EU /J)
- **Tanezumab** for osteoarthritis pain (US)[2]
- **Bamlanivimab + Etesevimab** EUA for COVID-19

[1] in collaboration with Boehringer Ingelheim
[2] in collaboration with Pfizer
[3] Japan approval occurred in Q4 2020

Q2 2021 PERFORMANCE SUMMARY

- **Volume-driven revenue growth** of 23%, with key growth products comprising the majority of revenue
- Non-GAAP operating margin of 29.4% with **continued expansion expected** throughout the year
- Progress on our **innovation-based strategy**, including positive data readouts for tirzepatide and Jardiance; additional Phase 3 initiations for pirtobrutinib, tirzepatide and Verzenio; and receipt of Breakthrough Therapy designation for donanemab
- Deployed nearly $800 million to shareholders via the dividend, completed $500 million in share repurchases and authorized a new $5 billion share repurchase program

Grow Revenue

Expect to deliver top-tier revenue growth

Improve Productivity

Non-GAAP operating margin expansion to the mid-to-high 30%s

Speed Life-Changing Medicines

- Potential to launch 20+ new molecules in 10 years (2014-2023)
- On average, could launch 2+ new indications or line extensions per year

Create Long-Term Value

- Fund existing marketed and pipeline products
- Bolster growth prospects via business development
- Annual dividend increases

SUPPLEMENTARY SLIDES

2021 INCOME STATEMENT – REPORTED

Millions; except per share data

	Q2 2021	Change
TOTAL REVENUE	$6,740	23%
GROSS MARGIN	71.0%	(6.8)pp
TOTAL OPERATING EXPENSE*	3,384	10%
OPERATING INCOME	1,403	17%
OPERATING MARGIN	20.8%	(0.9)pp
OTHER INCOME (EXPENSE)	191	(57)%
EFFECTIVE TAX RATE	12.8%	(1.3)pp
NET INCOME - CONTINUING OPERATIONS	$1,390	(2)%
EARNINGS PER SHARE	$1.53	(1)%

* Includes research and development expense, marketing, selling and administrative expense, acquired in-process research and development charges, and asset impairment, restructuring and other special charges.
NM – not meaningful

NON-GAAP GROSS MARGIN % OF REVENUE



Individual quarter GM % of Revenue:										
with FX effect on int'l inv sold	80.2%	81.0%	79.6%	79.9%	80.3%	79.6%	79.1%	78.6%	75.4%	79.3%
w/o FX effect on int'l inv sold	80.2%	80.2%	78.9%	79.6%	80.6%	79.1%	79.9%	79.1%	78.0%	79.7%

Note: The lines in the graph are moving annual totals (i.e. trailing 4 quarters) while the two rows of numbers are from specific quarters.

NON-GAAP OPERATING MARGIN % OF REVENUE



Individual quarter Op. Margin % of Revenue:										
with FX effect on int'l inv sold	26.2%	27.9%	28.6%	26.3%	30.1%	28.0%	26.2%	33.0%	27.5%	29.4%
w/o FX effect on int'l inv sold	26.2%	27.2%	27.9%	25.9%	30.4%	27.5%	27.0%	33.5%	30.1%	29.9%

Note: The lines in the graph are moving annual totals (i.e. trailing 4 quarters) while the two rows of numbers are from specific quarters.

EFFECT OF FX ON 2021 RESULTS

Year-on-Year Growth

REPORTED	Q2 2021		YTD 2021	
	With FX	w/o FX	With FX	w/o FX
TOTAL REVENUE	23%	20%	19%	17%
COST OF SALES	60%	50%	57%	45%
GROSS MARGIN	12%	11%	9%	9%
OPERATING EXPENSE	10%	8%	17%	16%
OPERATING INCOME	17%	18%	(8)%	(7)%
EARNINGS PER SHARE	(1)%	(1)%	(4)%	(3)%

NON-GAAP	Q2 2021		YTD 2021	
	With FX	w/o FX	With FX	w/o FX
TOTAL REVENUE	23%	20%	19%	17%
COST OF SALES	25%	16%	35%	22%
GROSS MARGIN	22%	21%	15%	15%
OPERATING EXPENSE	18%	16%	15%	13%
OPERATING INCOME	29%	30%	17%	19%
EARNINGS PER SHARE	29%	30%	22%	24%

EPS RECONCILIATION

	Q2 2021	Q2 2020	% Change	YTD 2021	YTD 2020	% Change
EPS (REPORTED)	**$1.53**	**$1.55**	**(1)%**	**$3.01**	**$3.15**	**(4)%**
COVID-19 ANTIBODIES EXCESS INVENTORY CHARGES	0.37			0.44		
ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT	0.02	0.25		0.28	0.30	
AMORTIZATION OF INTANGIBLE ASSETS	0.12	0.09		0.22	0.14	
ASSET IMPAIRMENT, RESTUCTURING AND OTHER SPECIAL CHARGES				0.19	0.06	
NET GAINS ON INVESTMENTS IN EQUITY SECURITIES	(0.16)	(0.44)		(0.41)	(0.58)	
EPS (NON-GAAP)	**$1.87**	**$1.45**	**29%**	**$3.74**	**$3.07**	**22%**

Note: Numbers may not add due to rounding; see slides 29 and 30 for more details on these significant adjustments.

Q2 2021 INCOME STATEMENT NOTES

Q2 2021 NON-GAAP INFORMATION HAS BEEN ADJUSTED TO ELIMINATE:

- amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties totaling $132.2 million (pretax), or $0.12 per share (after-tax);
- costs associated with upfront payments for acquired in-process research and development projects acquired in transactions other than a business combination, related to a business development transaction with MiNA Therapeutics Limited totaling $25.0 million (pretax), or $0.02 per share (after-tax);
- a charge resulting from excess inventory related to COVID-19 antibodies totaling $423.0 million (pretax), or $0.37 per share (after-tax); and
- gains and losses on investments in equity securities totaling $185.5 million (pretax), or ($0.16) per share (after-tax).

Q2 2020 NON-GAAP INFORMATION HAS BEEN ADJUSTED TO ELIMINATE:

- amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties totaling $102.8 million (pretax), or $0.09 per share (after-tax);
- costs associated with upfront payments for acquired in-process research and development projects acquired in a transaction other than a business combination, related to a business development transaction with a pre-clinical stage company as well as business development transactions with AbCellera Biologics Inc., Evox Therapeutics Limited, and Junshi Biosciences Co., Ltd. totaling $241.8 million (pretax), or $0.25 per share (after-tax); and
- gains and losses on investments in equity securities totaling $504.0 million (pretax), or ($0.44) per share (after-tax).

YTD 2021 INCOME STATEMENT NOTES

YTD 2021 NON-GAAP INFORMATION HAS BEEN ADJUSTED TO ELIMINATE:

- amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties totaling $257.9 million (pretax), or $0.22 per share (after-tax);
- costs associated with upfront payments for acquired in-process research and development projects acquired n a transaction other than a business combination, related to business development transactions with Rigel Pharmaceuticals, Inc., Precision Biosciences, Inc., Merus, N.V., Asahi Kasei Pharma Corporation and MiNA Therapeutics Limited totaling $324.3 million (pretax), or $0.28 per share (after-tax);
- charges resulting from excess inventory related to COVID-19 antibodies, an asset impairment resulting from the sale of the rights to QBREXZA and acquisition and integration costs recognized as part of the closing of the acquisition of Prevail Therapeutics Inc. totaling $716.1 million (pretax), or $0.63 per share (after-tax); and
- gains and losses on investments in equity securities totaling $472.0 million (pretax), or ($0.41) per share (after-tax).

YTD 2020 NON-GAAP INFORMATION HAS BEEN ADJUSTED TO ELIMINATE:

- amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties totaling $157.2 million (pretax), or $0.14 per share (after-tax);
- costs associated with upfront payments for acquired in-process research and development projects acquired in a transaction other than a business combination, related to both a business development transaction with a preclinical stage company as well as business development transactions with Sitryx Therapeutics Limited, AbCellera Biologics Inc., Evox Therapeutics Limited and Junshi Biosciences Co., Ltd. totaling $294.1 million (pretax), or $0.30 per share (after-tax);
- asset impairment, restructuring and other special charges, primarily the acquisition and integration costs related to the closing of the acquisition of Dermira, Inc. totaling $64.1 million (pretax), or $0.06 per share (after-tax); and
- gains and losses on investments in equity securities totaling $665.7 million (pretax), or ($0.58) per share (after-tax).

COMPARATIVE EPS SUMMARY 2020/2021

	1Q20	2Q20	3Q20	4Q20	2020	1Q21	2Q21	3Q21	4Q21	2021
Reported	1.60	1.55	1.33	2.32	6.79	1.49	1.53			
Non-GAAP	1.61	1.45	1.41	2.31	6.78	1.87	1.87			

Note: Numbers may not add due to rounding.

For a complete reconciliation to reported earnings, see slide 28 and our earnings press release dated August 3, 2021

Q2 2021 TRULICITY SALES INCREASED 25%

Millions

U.S. sales increased 20%
International sales increased 40%



U.S. TRx SOM and Market Volume



Source: IQVIA NPA TRx 3MMA, weekly data June 25, 2021; RA = rolling average
Note: TRx data is representative of the injectable GLP-1 market

Q2 2021 TALTZ SALES INCREASED 44%

Millions

U.S. sales increased 38%
International sales increased 60%



U.S. TRx SOM and Market Volume



Source: IQVIA NPA TRx 3MMA, weekly data June 25, 2021; RA = rolling average
Note: TRx data is representative of the full molecule market

Q2 2021 JARDIANCE SALES INCREASED 36%

Millions

U.S. sales increased 34%
International sales increased 39%



U.S. TRx SOM and Market Volume



Source: IQVIA NPA TRx 3MMA, weekly data June 25, 2021; RA = rolling average
Note: Jardiance is part of the Boehringer Ingelheim and Lilly Alliance

Q2 2021 VERZENIO SALES INCREASED 64%

Millions

U.S. sales increased 48%
International sales increased 97%



U.S. TRx SOM and Market Volume



Source: IQVIA NPA TRx 3MMA, weekly data June 25, 2021; RA = rolling average
Note: Q2 2020 IQVIA data was impacted by an addition of data for Verzenio

Q2 2021 CYRAMZA SALES INCREASED 5%

Millions

U.S. sales increased 8%
International sales increased 3%



Sales by Major Geography



Q2 2021 OLUMIANT SALES INCREASED 44%

Millions

U.S. sales were $18 million
International sales were $191 million



- Launched in the U.S. in July 2018
- Q2 sales driven by Germany and Japan
- Contributed ~120bps to Q2 WW volume growth

Q2 2021 EMGALITY SALES WERE $156 MILLION

Millions

U.S. sales were $112 million
International sales were $44 million



U.S. TRx SOM and Market Volume



Source: IQVIA NPA TRx 3MMA, weekly data June 25, 2021; RA = rolling average

Q2 2021 TYVYT SALES WERE $105 MILLION

Millions



- Launched in China in Q1 2019
- Part of Lilly collaboration with Innovent
- Contributed ~60bps to Q2 WW volume growth

Q2 2021 HUMALOG SALES INCREASED 9%

Millions

U.S. sales increased 17%
International sales increased 2%



U.S. TRx SOM



Source: IQVIA NPA TRx 3MMA, weekly data June 25, 2021

Q2 2021 BASAGLAR SALES DECREASED 27%

Millions

U.S. sales decreased 42%
International sales increased 27%



U.S. TRx SOM and Market Volume



Source: IQVIA NPA TRx 3MMA, weekly data June 25, 2021; RA = rolling average
Note: Basaglar is part of the Boehringer Ingelheim and Lilly Alliance

SELECT TRIALS – COVID-19 ANTIBODIES

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04427501[1]	COVID-19	A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness	2|3	3289	Percentage of Participants Who Experience COVID-Related Hospitalization or Death from Any Cause	Sep 2020	Jun 2022
NCT04634409[1]	COVID-19	A Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants with Mild to Moderate COVID-19 Illness (BLAZE-4)	2	1556	Percentage of Participants with SARS-CoV-2 Viral Load Greater than 5.27	Aug 2021	Nov 2021

[1] In collaboration with AbCellera Biologics Inc. and Junshi Bioscience Co., Ltd.

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 21, 2021

SELECT TRIALS – DONANEMAB

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT03367403	Alzheimer's Disease	A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)	2	266	Change from Baseline in the Integrated Alzheimer's Disease Rating Scale (iADRS) Score	Dec 2020	Nov 2021
NCT04437511	Alzheimer's Disease	A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)	3	1500	Change from Baseline on the integrated Alzheimer's Disease Rating Scale (iADRS)	Mar 2023	Dec 2023
NCT04640077	Alzheimer's Disease	A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)	2	100	Part A: Correlation between VTC and on-site assessment for PAIR 1 for Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13)	May 2023	Oct 2023

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 16, 2021

SELECT TRIALS – JARDIANCE

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT03594110[1]	Chronic Kidney Disease	EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)	3	6609	Composite primary outcome:Time to first occurrence of (i) kidney disease progression (defined as ESKD, a sustained decline in eGFR to <10 mL/min/1.73m^2, renal death, or a sustained decline of ≥40% in eGFR from randomization) or (ii) Cardiovascular death	Nov 2022	Dec 2022
NCT04509674	Myocardial Infarction	EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)	3	3312	Composite of time to first heart failure hospitalisation or all-cause mortality	Dec 2022	Dec 2022

In collaboration with Boehringer Ingelheim
[1] Also lists Medical Research Council Population Health Research Unit, CTSU, University of Oxford (academic lead)

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 13, 2021

SELECT TRIALS – LEBRIKIZUMAB

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04146363	Atopic Dermatitis	Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)	3	400	Percentage of participants with an IGA score of 0 or 1 and a reduction ≥2 points from Baseline to Week 16	Jun 2021	Feb 2022
NCT04178967	Atopic Dermatitis	Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis	3	400	Percentage of participants with an IGA score of 0 or 1 and a reduction ≥2 points from Baseline to Week 16	Jul 2021	Jun 2022
NCT04250337	Atopic Dermatitis	Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.	3	225	The primary efficacy endpoint is the percentage of participants with an IGA score of 0 or 1 and a reduction ≥2 points from Baseline to Week 16.	Aug 2021	Oct 2021
NCT04626297	Atopic Dermatitis	A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)	3	240	Percentage of Participants who Develop a Booster Response to Tetanus Toxoid 4 Weeks after Vaccine Administration	Nov 2021	Jan 2022
NCT04250350	Atopic Dermatitis	Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis	3	200	Percentage of Participants Discontinued from Study Treatment Due to Adverse Events	Apr 2022	Jul 2022
NCT04760314	Atopic Dermatitis	A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis	3	280	Percentage of Participants with an Investigators Global Assessment (IGA) score of 0 or 1 and a reduction ≥2 points from Baseline to Week 16	Oct 2022	May 2023
NCT04392154	Atopic Dermatitis	Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)	3	1000	Percentage of Participants Discontinued from Study Treatment due to Adverse Events through the Last Treatment Visit	May 2024	May 2024

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 20, 2021

SELECT TRIALS – LYUMJEV

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT03740919	Type 1 Diabetes Mellitus	A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes	3	945	Change from Baseline in Hemoglobin A1c (HbA1c) (Prandial Dosing)	Jul 2021	Jul 2021
NCT03952130	Type 1 Diabetes Mellitus	A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes	3	350	Change from Baseline in Hemoglobin A1c (HbA1c)	Dec 2021	Dec 2021
NCT04605991	Type 2 Diabetes	A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)	3	167	Change from Baseline in Percentage of Time with CGM Glucose Values between 70-180 milligrams/deciliter (mg/dL) (3.9-10.0 millimoles/Liter [mmol/L]) (both inclusive) during Daytime Period with 14 Days of CGM Use	Dec 2021	Dec 2021

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 16, 2021

SELECT TRIALS – MIRIKIZUMAB

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT03556202	Psoriasis	A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)	3	1816	Percentage of Participants with a Static Physician's Global Assessment Among Those who Entered the Study with a sPGA of 0,1(sPGA) of (0,1)	Jan 2022	Jan 2022
NCT03926130	Crohn's Disease	A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease	3	1150	Percentage of Participants Achieving Endoscopic Response	Dec 2022	Apr 2023
NCT04232553	Crohn's Disease	A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease	3	778	Percentage of Participants Achieving Endoscopic Response	Jun 2024	Jun 2024
NCT03518086	Ulcerative Colitis	An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)	3	1160	Percentage of Participants in Clinical Remission	Jan 2021	Oct 2022
NCT03524092	Ulcerative Colitis	A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis	3	1044	Percentage of Participants in Clinical Remission	Nov 2021	Aug 2023
NCT03519945	Ulcerative Colitis	A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)	3	960	Percentage of Participants in Clinical Remission	Aug 2023	Jul 2025

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 19, 2021

SELECT TRIALS – OLUMIANT

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT03899259	Alopecia Areata	A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata	3	476	Percentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤20	Jan 2021	May 2024
NCT03570749	Alopecia Areata	A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata	2|3	725	Percentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤20	Feb 2021	Jun 2024
NCT03616964	Systemic Lupus Erythematosus	A Study of Baricitinib in Participants With Systemic Lupus Erythematosus	3	750	Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response (High Dose)	Oct 2021	Nov 2021
NCT03616912[1]	Systemic Lupus Erythematosus	A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus	3	809	Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response (High Dose)	May 2022	Jun 2022

In collaboration with Incyte
[1] Primary completion excluding extension in Nov 2021

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 19, 2021

SELECT TRIALS – PIRTOBRUTINIB

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04849416	Chronic Lymphocytic Leukemia	A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)	2	126	Overall Response Rate (ORR)	Aug 2022	Apr 2025
NCT03740529	Chronic Lymphocytic Leukemia	A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL	1|2	860	Maximum Tolerated Dose (MTD)	Feb 2023	May 2023
NCT04666038	Chronic Lymphocytic Leukemia	Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With CLL or SLL	3	250	To evaluate progression-free survival (PFS) of LOXO-305 monotherapy (Arm A) compared to investigator's choice of idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR) (Arm B)	Jan 2024	Jun 2024
NCT04965493	Chronic Lymphocytic Leukemia	A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)	3	600	To evaluate progression-free survival (PFS) of pirtobrutinib plus venetoclax and rituximab (Arm A) compared to venetoclax and rituximab (Arm B)	Oct 2025	Jan 2027
NCT04662255	Lymphoma, Mantle-Cell	Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)	3	500	To compare progression-free survival (PFS) of LOXO-305 as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor monotherapy (Arm B) in patients with previously treated mantle cell lymphoma (MCL)	Aug 2024	Feb 2025

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 16, 2021

SELECT TRIALS – RETEVMO

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT03899792	Medullary Thyroid Cancer	A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors	1|2	100	To Determine the Safety of Oral LOXO-292 in Pediatric Participants with Advanced Solid Tumors: Dose Limiting Toxicities (DLTs)	Mar 2023	Mar 2024
NCT04211337	Medullary Thyroid Cancer	A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer	3	400	Treatment Failure-Free Survival (TFFS) by Blinded Independent Committee Review (BICR)	May 2024	Nov 2026
NCT03157128	Non-Small Cell Lung Cancer	A Study of LOXO-292 in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer	1|2	989	Phase 1: MTD	Nov 2022	Nov 2023
NCT04194944	Non-Small Cell Lung Cancer	A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer	3	250	Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) (with Pembrolizumab)	Jan 2023	Aug 2025
NCT04819100	Non-Small Cell Lung Cancer	A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)	3	170	Event-Free Survival (EFS)	Aug 2028	Nov 2032
NCT04280081	Solid Tumor	A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation	2	75	Overall Response Rate (ORR): Percentage of Participants with Complete Response (CR) or Partial Response (PR) by Independent Review Committee	Mar 2021	Nov 2025

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 19, 2021

SELECT TRIALS – SOLANEZUMAB

Study	Indication	Title	Phase	Patients	Primary Outcome*	Primary Completion	Completion
NCT02008357[1]	Cognition Disorders	Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss	3	1150	Change from Baseline of the Preclinical Alzheimer Cognitive Composite (PACC)	Dec 2022	Dec 2022

[1] Also lists Alzheimer's Therapeutic Research Institute

* Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 26, 2021

SELECT TRIALS – TIRZEPATIDE

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04166773	Nonalcoholic Steatohepatitis	A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)	2	196	Percentage of Participants with Absence of NASH with no Worsening of Fibrosis on Liver Histology	Jun 2022	Jun 2022
NCT04184622	Obesity	A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight	3	2400	Percent Change from Baseline in Body Weight	Apr 2022	May 2024
NCT04657003	Obesity	A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight	3	900	Percent Change from Randomization in Body Weight	Jun 2023	Jul 2023
NCT04660643	Obesity	A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss	3	750	Percent Change from Randomization (Week 36) in Body Weight	Aug 2023	Aug 2023
NCT04657016	Obesity	A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program	3	800	Percent Change from Randomization in Body Weight	Aug 2023	Sep 2023
NCT04844918	Obesity	A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease	3	261	Percentage of Participants who Achieve ≥5% Body Weight Reduction	Aug 2023	Aug 2023
NCT04847557	Obesity	A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT)	3	700	A Hierarchical Composite of All-Cause Mortality, Heart Failure Events, 6-minute Walk Test Distance (6MWD) and Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS) Category	Nov 2023	Nov 2023

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 20, 2021

SELECT TRIALS – TIRZEPATIDE (CONT.)

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04093752	Type 2 Diabetes	A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)	3	917	Mean Change from Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)	Oct 2021	Nov 2021
NCT04537923	Type 2 Diabetes	A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin	3	1182	Change from Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses)	Oct 2022	Nov 2022
NCT04255433	Type 2 Diabetes	A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes	3	12500	Time to First Occurrence of Death from Cardiovascular (CV) Causes, Myocardial Infarction (MI), or Stroke (MACE-3)	Oct 2024	Oct 2024

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 19, 2021

SELECT TRIALS – VERZENIO

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT03155997[1]	Breast Cancer	Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer	3	5637	Invasive Disease Free Survival (IDFS)	Mar 2020	Jun 2029
NCT04752332	Breast Cancer	A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer	3	2450	Invasive Disease Free Survival (IDFS)	May 2025	Feb 2033
NCT03706365	Prostate Cancer	A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer	2|3	350	Radiographic Progression Free Survival (rPFS)	Dec 2023	Jun 2026

[1] Also lists NSABP Foundation Inc

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 27, 2020

SELECT TRIALS – EARLY PHASE DIABETES

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Basal Insulin - FC	NCT04450407	Type 1 Diabetes	A Study of LY3209590 in Participants With Type 1 Diabetes	2	254	Change from Baseline in Hemoglobin A1c (HbA1c)	Sep 2021	Sep 2021
Basal Insulin - FC	NCT04450394	Type 2 Diabetes	A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus	2	264	Change from Baseline in Hemoglobin A1c (HbA1c)	Oct 2021	Oct 2021
GGG Tri-Agonist	NCT04867785	Type 2 Diabetes	A Study of LY3437943 in Participants With Type 2 Diabetes	2	300	Change from Baseline in Hemoglobin A1c (HbA1c)	Mar 2022	Jul 2022
GGG Tri-Agonist	NCT04881760	Obesity	A Study of LY3437943 in Participants Who Have Obesity or Are Overweight	2	300	Mean Percent Change in Body Weight	May 2022	Sep 2022
KHK Inhibitor	NCT04270370	Healthy	A Study of LY3478045 in Healthy Participants	1	72	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug	Jun 2021	Jun 2021
Oxyntomodulin	NCT03928379	Type 2 Diabetes	A Study of LY3305677 in Participants With Type 2 Diabetes	1	24	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug	Jul 2021	Jul 2021
GLP-1R NPA	NCT04426474	Type 2 Diabetes	A Study of LY3502970 in Participants With Type 2 Diabetes	1	60	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug	Jul 2021	Jul 2021

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 7, 2021

SELECT TRIALS – EARLY PHASE DIABETES (CONT.)

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Basal Insulin - FC	NCT04768842	Healthy	A Study of Two Different Formulations of LY3209590 in Healthy Participants	1	50	Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3209590	Sep 2021	Sep 2021
GIP/GLP Coagonist Peptide	NCT04682106	Healthy	A Study of LY3493269 in Healthy Participants	1	56	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Sep 2021	Sep 2021
KHK Inhibitor II	NCT04559568	Healthy	A Study of LY3522348 in Healthy Participants	1	100	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Aug 2021	Sep 2021
PYY Analog Agonist	NCT04641312	Healthy	A Study of LY3457263 in Healthy Participants and Participants With Type 2 Diabetes	1	90	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Sep 2021	Sep 2021
LP(a) Inhibitor	NCT04472676	Healthy	A Study of LY3473329 in Healthy Participants	1	107	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Oct 2021	Dec 2021
GIPR Agonist LA II	NCT04923269	Healthy	A Study of LY3532226 in Healthy Participants	1	50	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Nov 2021	Nov 2021

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 7, 2021

SELECT TRIALS – EARLY PHASE DIABETES (CONT.)

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
GIPR Agonist LA	NCT04586907	Healthy	A Study of LY3537021 in Healthy Participants and Participants With Type 2 Diabetes Mellitus	1	95	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Nov 2021	Nov 2021
GGG Tri-Agonist	NCT04823208	Type 2 Diabetes	A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)	1	66	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Jan 2022	Jan 2022
Relaxin-LA	NCT04768855	Healthy	A Study of LY3540378 in Healthy Participants	1	120	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Mar 2022	Mar 2022
ANGPTL-siRNA	NCT04644809	Dyslipidemias	A Study of LY3561774 in Participants With Dyslipidemia	1	74	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Apr 2022	Apr 2022
LP(a)-siRNA	NCT04914546	Healthy	A Study of LY3819469 in Healthy Participants	1	66	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Oct 2022	Oct 2022
NRG4 Agonist I	NCT04840914	Chronic Heart Failure With Reduced Ejection Fraction	A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction	1	50	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Feb 2023	Feb 2023

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 7, 2021

SELECT TRIALS – EARLY PHASE IMMUNOLOGY

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
CXCR1/2L mAb	NCT04493502	Hidradenitis Suppurativa	A Study of LY3041658 in Adults With Hidradenitis Suppurativa	2	52	Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR)	Dec 2021	Jul 2022
PD-1 Mab Agonist	NCT04634253	Rheumatoid Arthritis	A Study of LY3462817 in Participants With Rheumatoid Arthritis	2	80	Change from Baseline on the Disease Activity Score Modified to Include the 28 Diarthrodial Joint Count-High-Sensitivity C-Reactive Protein (DAS28-hsCRP)	Feb 2022	Aug 2022
IL-2 CONJUGATE[1]	NCT04433585	Systemic Lupus Erythematosus	A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)	2	280	Percentage of Participants who Achieve a ≥4 Point Reduction in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) 2000 (2K) Score	Nov 2022	Feb 2023
IL-2 CONJUGATE[1]	NCT04677179	Colitis, Ulcerative	A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)	2	200	Percentage of Participants in Clinical Remission	Nov 2023	Oct 2024
CD200R MAB Agonist	NCT03750643	Dermatitis, Atopic	A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis	1	64	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Jun 2021	Aug 2021
IL-2 CONJUGATE[1]	NCT04119557	Psoriasis	A Study of LY3471851 in Participants With Psoriasis	1	40	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Jul 2021	Jul 2021

[1] Also lists Nektar Therapeutics

* Molecule may have multiple indications

** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 19, 2021

SELECT TRIALS – EARLY PHASE IMMUNOLOGY (CONT.)

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
IL-17A Small Molecule Inhibitor	NCT04586920	Healthy	A Study of LY3509754 in Healthy Non-Japanese and Japanese Participants	1	121	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Sep 2021	Sep 2021
PD-1 Mab Agonist	NCT04152382	Psoriasis	A Safety Study of LY3462817 in Participants With Psoriasis	1	64	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Apr 2022	Apr 2022
IL-2 CONJUGATE[1]	NCT04081350	Dermatitis, Atopic	A Study of LY3471851 in Participants With Eczema	1	40	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Aug 2022	Aug 2022
BTLA MAB Agonist	NCT04975295	Psoriasis	A Study of LY3361237 in Participants With Psoriasis	1	24	Number of Participants with One or More Treatment-Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Oct 2022	Oct 2022

[1] Also lists Nektar Therapeutics

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 23, 2021

SELECT TRIALS – EARLY PHASE NEURODEGENERATION

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Zagotenemab (Tau MAB)	NCT03518073	Alzheimer's Disease	A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease	2	285	Change from Baseline on the integrated Alzheimer's Disease Rating Scale (iADRS)	Aug 2021	Oct 2021
O-GlcNAcase Inh.	NCT04392271	Healthy	A Study of the Effects of Multiple Doses of LY3372689 on the Brain in Healthy Participants	1	4	Percent O-GlcNAcase (OGA) Enzyme Occupancy (EO)	Oct 2020	Oct 2020
Mevidalen (D1 PAM)	NCT04258826	Healthy	A Study to Evaluate LY3154207 on the Brain of Healthy Participants	1	34	Change from Baseline in Intrinsic Functional Connectivity Among Resting-State Networks of the Brain	Nov 2021	Nov 2021
N3PG Aß MAB	NCT04451408	Alzheimer's Disease	A Study of LY3372993 in Participants With Alzheimer's Disease (AD)	1	30	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Apr 2022	Apr 2022
GBA1 Gene Therapy	NCT04127578	Parkinson's Disease	Phase 1/2a Clinical Trial of PR001 in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)	1|2	12	Number of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)	Jun 2027	Jun 2027
GRN Gene Therapy	NCT04408625	Frontotemporal Dementia	Phase 1/2 Clinical Trial of PR006 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)	1|2	15	Number of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events Leading to discontinuation	Sep 2027	Sep 2027
GBA1 Gene Therapy	NCT04411654	Gaucher Disease, Type 2	Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)	1|2	15	Number of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events leading to discontinuation	Sep 2028	Sep 2028

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 8, 2021

SELECT TRIALS – EARLY PHASE ONCOLOGY

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
SERD	NCT04840888	Healthy	A Study of LY3484356 in Healthy Female Participants	1	60	Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3484356	Jul 2021	Jul 2021
SERD	NCT04188548	Breast Cancer	A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer	1	500	Number of Participants with Dose Limiting Toxicities (DLTs) and DLT-Equivalent Toxicities	Jul 2021	Apr 2023
SERD	NCT04647487	Breast Cancer	A Study of LY3484356 in Women With Breast Cancer Before Having Surgery	1	60	Change from Baseline in ER Expression	Mar 2022	Mar 2022
IDH1 Inhibitor	NCT04603001	Acute Myeloid Leukemia (AML)	Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations	1	220	To determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D)	Feb 2023	Sep 2023
SERD	NCT04975308	Breast Cancer	Study of LY3484356 Versus Hormone Therapy in Participants Breast Cancer	3	500	Progression Free Survival (PFS)	Mar 2023	Mar 2026
IDH1 Inhibitor	NCT04521686	Cholangiocarcinoma	Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 Mutations	1	180	Recommended Phase 2 dose (RP2D)	Feb 2023	Sep 2023
Aur A Kinase Inhibitor[1]	NCT04106219	Neuroblastoma	A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma	1	71	Number of Participants with Dose Limiting Toxicities (DLTs)	Apr 2024	Apr 2025

[1] Also lists New Approaches to Neuroblastoma Therapy Consortium (NANT) and Innovative Therapies for Children with Cancer in Europe (ITCC)

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 16, 2021

SELECT TRIALS – EARLY PHASE PAIN

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
EPIREG/TGFa MAB	NCT04456686	Osteoarthritis	Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Osteoarthritis	2	125	Change from Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)	Apr 2021	Sep 2022
EPIREG/TGFa MAB	NCT04529096	Chronic Low-back Pain	Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Chronic Low Back Pain	2	150	Change from Baseline for Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)	Jun 2021	Nov 2022
EPIREG/TGFa MAB	NCT04476108	Diabetic Peripheral Neuropathic Pain	Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Diabetic Peripheral Neuropathic Pain	2	125	Change from Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)	Jul 2021	Jan 2023
PACAP38 MAB	NCT04498910	Migraine	A Study of LY3451838 in Participants With Migraine	2	120	Change from Baseline in the Number of Monthly Migraine Headache Days	Nov 2021	Nov 2021
SSTR4 Agonist	NCT04627038	Osteoarthritis	Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Osteoarthritis	2	200	Change from Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)	Dec 2021	Dec 2021
SSTR4 Agonist	NCT04874636	Chronic Low-back Pain	Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Chronic Low Back Pain	2	200	Change from Baseline for Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)	Jan 2022	Jan 2022

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 16, 2021

SELECT TRIALS – EARLY PHASE PAIN (CONT.)

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
SSTR4 Agonist	NCT04707157	Diabetic Peripheral Neuropathic Pain	Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Diabetic Peripheral Neuropathic Pain	2	200	Change from Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)	Apr 2022	Apr 2022
TRPA1 Antagonist I	NCT04682119	Healthy	A Safety Study of LY3526318 in Healthy Participants	1	16	Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3526318	Apr 2021	Apr 2021

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 16, 2021


Lilly